[PDF] Guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes - Full guideline

Source:
Scottish Intercollegiate Guidelines Network - SIGN
Publisher:
Scottish Intercollegiate Guidelines Network (SIGN)
Publication date:
01 November 2017

Abstract

(2017) Guideline 154: Management of diabetes - Full guideline. The Scottish Intercollegiate Guidelines Network (SIGN) develops evidence based clinical practice guidelines for the National Health Service (NHS) in Scotland. SIGN guidelines are derived from a systematic review of the scientific literature and are designed as a vehicle for accelerating the translation of new knowledge into action to meet our aim of reducing variations in practice, and improving patient-important outcomes.

This guideline provides recommendations on:

  • optimal targets for glucose control for the prevention of microvascular and macrovascular complications in people with type 2 diabetes (moved unchanged from SIGN 116), and
  • the risks and benefits of the principal therapeutic classes of glucose-lowering agents and insulins currently available for people with type 2 diabetes who require measures beyond diet and exercise to achieve glucose targets (updated from SIGN 116).